

Table 1. VPA, ESM, PBL, CBD and CBDV effects on motor performance. Results are mean±SEM. *= $p \leq 0.05$, **= $p \leq 0.01$ and ***= $p \leq 0.001$. Chi squared or ANOVA with post hoc Tukey where appropriate.

These results show CBDV is a well-tolerated and effective anti-convulsant in rat with significant clinical potential for the treatment of epilepsy.

Work funded, and phytocannabinoids provided, by GW Pharmaceuticals & Otsuka Pharmaceuticals.

JONES, N. A., HILL, A. J., SMITH, I., BEVAN, S. A., WILLIAMS, C. M., WHALLEY, B. J. & STEPHENS, G. J. (2010) Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. *Journal of Pharmacology and Experimental Therapeutics*, 332, 569.

HILL, A. J., JONES, N. A., STEPHENS, G. J., WILLIAMS, C. M. & WHALLEY, B. J. (2010) Anticonvulsant effects of GWP42006 in vitro and in vivo in rat. *Proceedings Physiological Society*, 19.